Which has preferable valuation & earnings, AGFY or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Agrify. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agrify $12.26M 3.63 -$41.75M -$22.65 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Do analysts rate PHXM or ATHE?

Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 108.77%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, PHXM or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is PHXM or ATHE more profitable?

Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A Alterity Therapeutics N/A N/A N/A

Do analysts prefer RFAI or PHXM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, RFAI or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is RFAI or PHXM more profitable?

Company Net Margins Return on Equity Return on Assets RF Acquisition Corp II N/A N/A N/A PHAXIAM Therapeutics N/A N/A N/A

Do analysts prefer VERU or PHXM?

Veru currently has a consensus price target of $24.50, suggesting a potential upside of 797.44%. Given Veru's stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, VERU or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Veru. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru $16.89M 2.76 -$22.73M -$0.89 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is VERU or PHXM more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% PHAXIAM Therapeutics N/A N/A N/A

Which has higher valuation and earnings, PHXM or ADXS?

PHAXIAM Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A Ayala Pharmaceuticals $3.24M 11.05 -$48.07M -$5.02 N/A

Is PHXM or ADXS more profitable?

Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A Ayala Pharmaceuticals N/A N/A N/A

PHAXIAM Therapeutics (PHXM) Competitors

$3.10 0.00 (0.00%)

As of 08/13/2026

Compare

PHXM vs. AGFY, ATHE, RFAI, VERU, and ADXS

Should you buy PHAXIAM Therapeutics stock or one of its competitors? PHAXIAM Therapeutics's main competitors and comparable companies include Agrify (AGFY), Alterity Therapeutics (ATHE), RF Acquisition Corp II (RFAI), Veru (VERU), and Ayala Pharmaceuticals (ADXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PHAXIAM Therapeutics compare to Agrify?

Agrify (NASDAQ:AGFY) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

6.0% of Agrify shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 2.2% of Agrify shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Agrify's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
Agrify	Neutral
PHAXIAM Therapeutics	Neutral

Agrify has a beta of 9.96, suggesting that its share price is 896% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

PHAXIAM Therapeutics has a net margin of 0.00% compared to Agrify's net margin of -424.11%. PHAXIAM Therapeutics' return on equity of 0.00% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
PHAXIAM Therapeutics	N/A	N/A	N/A

PHAXIAM Therapeutics has lower revenue, but higher earnings than Agrify.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.63	-$41.75M	-$22.65	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

Agrify and PHAXIAM Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 108.77%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Alterity Therapeutics had 6 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 6 mentions for Alterity Therapeutics and 0 mentions for PHAXIAM Therapeutics. Alterity Therapeutics' average media sentiment score of 0.65 beat PHAXIAM Therapeutics' score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Alterity Therapeutics	Positive

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats PHAXIAM Therapeutics on 7 of the 9 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to RF Acquisition Corp II?

RF Acquisition Corp II (NASDAQ:RFAI) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

In the previous week, RF Acquisition Corp II had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for RF Acquisition Corp II and 0 mentions for PHAXIAM Therapeutics. RF Acquisition Corp II's average media sentiment score of 1.42 beat PHAXIAM Therapeutics' score of 0.00 indicating that RF Acquisition Corp II is being referred to more favorably in the media.

Company	Overall Sentiment
RF Acquisition Corp II	Positive
PHAXIAM Therapeutics	Neutral

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 39.1% of RF Acquisition Corp II shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
PHAXIAM Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

RF Acquisition Corp II beats PHAXIAM Therapeutics on 4 of the 5 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Veru?

Veru (NASDAQ:VERU) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Veru currently has a consensus price target of $24.50, suggesting a potential upside of 797.44%. Given Veru's stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PHAXIAM Therapeutics has lower revenue, but higher earnings than Veru.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.76	-$22.73M	-$0.89	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

In the previous week, Veru had 9 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 9 mentions for Veru and 0 mentions for PHAXIAM Therapeutics. Veru's average media sentiment score of 1.10 beat PHAXIAM Therapeutics' score of 0.00 indicating that Veru is being referred to more favorably in the media.

Company	Overall Sentiment
Veru	Positive
PHAXIAM Therapeutics	Neutral

Veru has a beta of -1.15, indicating that its share price is 215% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

PHAXIAM Therapeutics' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
PHAXIAM Therapeutics	N/A	N/A	N/A

47.2% of Veru shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Veru beats PHAXIAM Therapeutics on 8 of the 12 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Ayala Pharmaceuticals?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Ayala Pharmaceuticals	Neutral

PHAXIAM Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Ayala Pharmaceuticals	N/A	N/A	N/A

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

PHAXIAM Therapeutics beats Ayala Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHXM vs. The Competition

Export

Metric	PHAXIAM Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.58M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	N/A	775.15	269.06	25.28
Price / Sales	N/A	743.86	602.43	91.76
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.39	11.60	12.91	6.24
Net Income	-$240K	$2.77B	$3.45B	$347.60M
7 Day Performance	N/A	0.17%	1.12%	1.07%
1 Month Performance	N/A	0.35%	1.79%	1.03%
1 Year Performance	N/A	161.52%	67.69%	20.77%

PHAXIAM Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
AGFY Agrify	N/A	$20.65 +14.0%	N/A	-33.6%	$41.36M	$12.26M	N/A	140
ATHE Alterity Therapeutics	4.0887 of 5 stars	$4.39 -1.6%	$13.00 +196.1%	-9.9%	$39.52M	N/A	N/A	10	News Coverage Analyst Forecast Short Interest Decrease
RFAI RF Acquisition Corp II	1.9506 of 5 stars	$11.09 0.0%	N/A	+4.6%	$38.95M	N/A	N/A	N/A	News Coverage Earnings Report Short Interest Decrease
VERU Veru	2.2389 of 5 stars	$2.37 +4.9%	$23.00 +870.5%	-20.8%	$36.27M	$16.89M	N/A	230	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. AGFY, ATHE, RFAI, VERU, and ADXS

How does PHAXIAM Therapeutics compare to Agrify?

Summary

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

Summary

How does PHAXIAM Therapeutics compare to RF Acquisition Corp II?

Summary

How does PHAXIAM Therapeutics compare to Veru?

Summary

How does PHAXIAM Therapeutics compare to Ayala Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. AGFY, ATHE, RFAI, VERU, and ADXS

How does PHAXIAM Therapeutics compare to Agrify?

Do insiders and institutionals believe in AGFY or PHXM?

Does the media prefer AGFY or PHXM?

Which has more volatility & risk, AGFY or PHXM?

Is AGFY or PHXM more profitable?

Which has preferable valuation & earnings, AGFY or PHXM?

Summary

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

Which has better valuation and earnings, PHXM or ATHE?

Which has more risk and volatility, PHXM or ATHE?

Do institutionals and insiders believe in PHXM or ATHE?

Do analysts rate PHXM or ATHE?

Does the media favor PHXM or ATHE?

Is PHXM or ATHE more profitable?

Summary

How does PHAXIAM Therapeutics compare to RF Acquisition Corp II?

Does the media refer more to RFAI or PHXM?

Do institutionals & insiders hold more shares of RFAI or PHXM?

Do analysts prefer RFAI or PHXM?

Is RFAI or PHXM more profitable?

Which has higher valuation & earnings, RFAI or PHXM?

Summary

How does PHAXIAM Therapeutics compare to Veru?

Do analysts prefer VERU or PHXM?

Which has higher earnings & valuation, VERU or PHXM?

Does the media prefer VERU or PHXM?

Which has more risk and volatility, VERU or PHXM?

Is VERU or PHXM more profitable?

Do institutionals & insiders have more ownership in VERU or PHXM?

Summary

How does PHAXIAM Therapeutics compare to Ayala Pharmaceuticals?

Does the media refer more to PHXM or ADXS?

Which has higher valuation and earnings, PHXM or ADXS?

Which has more volatility & risk, PHXM or ADXS?

Is PHXM or ADXS more profitable?

Do institutionals & insiders believe in PHXM or ADXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools